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Inflammation is an important feature of the pathophysiological response to
ischaemic stroke. The ischaemic brain-invading leukocytes, neutrophils in particu-
lar, contribute to the exacerbation of tissue injury in stroke. Chemokines are
a growing family of proteins performing chemotactic activity on selective leukocyte
subpopulations. Chemokines are broadly divided into two major subfamilies on
the basis of the arrangement of the two N-terminal cysteine residues, CXC and CC,
depending on whether the first two cysteine residues have an amino acid be-
tween them (CXC) or are adjacent (CC). CXC chemokines possessing, close to the
N terminus, the amino acid sequence glutamic acid-leucine-arginine (ELR motif)
specifically act on neutrophils. CXCL5 is one of the ELR-expressing CXC chemok-
ines and is a potent neutrophil attractant and activator. The objective of the study
was to detect CXCL5 levels in the cerebrospinal fluid (CSF) and sera of stroke
patients and to investigate the relation between these levels and the volume of
brain computed tomography (CT) hypodense areas representing early ischaemic
lesions. A total of 23 ischaemic stroke patients were studied. CSF and blood sam-
pling and brain CT were performed within the first 24 hours of stroke. The control
group consisted of 15 patients with tension headache. CXCL5 levels were deter-
mined by the ELISA method. CSF CXCL5 levels in stroke patients were significantly
higher in comparison with the control group (38.2 ± 18.4 pg/ml vs. 18.7 ±
± 8.2 pg/ml; p < 0.001). No significant differences in serum CXCL5 levels were
found between the stroke patients and the control group. CSF CXCL5 levels corre-
lated positively with the volume of early brain CT hypodense areas (p < 0.0001).
The results suggest that CXCL5 may play a role in the inflammatory reaction dur-
ing the early phase of ischaemic stroke.
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INTRODUCTION
Inflammatory reaction is an important feature of
the pathophysiological response to ischaemic stroke.
The local intracerebral influx of leukocytes, neutro-
phils in particular, contributes to the exacerbation
of tissue injury in stroke [4, 9].
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Chemokines (an abbreviation for “chemoattractant
cytokines”) constitute a growing family of structurally
and functionally related small (8–14 kDa) proteins
which perform chemotactic activity on selective leuko-
cyte subpopulations [6, 8, 25] and which, it is now
postulated, play a substantial role in the accumulation
of leukocytes within an ischaemic brain lesion [15, 16].
Chemokines are broadly divided into two major
subfamilies on the basis of the arrangement of the
two N-terminal cysteine residues, CXC and CC, de-
pending on whether the first two cysteine residues
have an amino acid between them (CXC) or are ad-
jacent (CC) [25]. CXC subfamily is further subdivided
into those chemokines that contain the amino acid
sequence glutamic acid-leucine-arginine (the ELR
motif) close to the N terminus and those which do
not [8]. This subdivision has functional significance,
as ELR-expressing CXC chemokines chemoattract
neutrophils, whereas non-ELR CXC chemokines as
well as CC chemokines are chemotactic towards
mononuclear cells [18].
In the settings of experimental and clinical stroke
CXC and CC chemokines have been found to be ex-
pressed by brain-resident cells such as microglia,
astrocytes, neurons and endothelia, and/or by the
ischaemic brain-invading as well as circulating leu-
kocytes [6, 10, 11, 16, 22]. Experimental models of
cerebral ischaemia have shown that expression of
CXC and CC chemokines precedes relevant leukocyte
infiltration [10, 22, 23].
Increased levels of CXC and CC chemokines have
been found in the cerebrospinal fluid (CSF) or periph-
eral blood of ischaemic stroke patients [11–13, 20].
CXCL5, originally described as an epithelial cell-
derived neutrophil-activating protein consisting of
78 amino acids (ENA-78), is a potent neutrophil at-
tractant and activator belonging to CXC chemokine
subfamily which possesses the ELR motif [8]. CXCL5
exhibits extensive structural and functional similari-
ty to other ELR-expressing CXC chemokines [8]. In
particular, CXCL5 is highly homologous to CXCL6
(primarily termed granulocyte chemotactic protein
(GCP-2), and these two chemokines are 80% and 88%
identical at the amino acid and nucleic acid levels
respectively [24, 25]. The gene for CXCL5 has been
mapped to chromosome 4q12-q13 [25]. CXCL5 ex-
erts its biological effects mainly through interaction
with the CXCR2 receptor [6]. Increased CXCL5 ex-
pression has been found to be associated with neu-
trophil influx in several inflammatory conditions [3].
Following stroke, neutrophils are the first leu-
kocyte subpopulation to migrate into the infarct
zone. The neutrophil response progressively in-
creases within the first 24 hours of the disease,
and there is a positive correlation between neu-
trophil accumulation and the magnitude of the
ischaemic brain damage [1]. It is therefore intrigu-
ing whether CXCL5 with its neutrophil chemoat-
tractant properties may be involved in the early
phase of ischaemic stroke.
The study was focused on two goals. The first
was to determine CXCL5 levels in CSF and serum of
ischaemic stroke patients within the first 24 hours
of the disease and to compare the results with those
of a control group. The second was to study wheth-
er the levels of CXCL5 in the stroke patients within
the first 24 hours of the disease may be related to
the volume of early brain (computed tomography) CT
hypodense areas observed at the same period, indi-
cating early ischaemic stroke-related brain lesions.
So far CXCL5 has been studied neither in experi-
mental nor in clinical ischaemic stroke.
MATERIAL AND METHODS
Patients
The study involved 23 first-ever ischaemic stroke
patients (mean age ± SD: 72.2 ± 10.8 years,
17 women) admitted between the 6th and the 20th
hour (median = 12th h) after the onset of symptoms.
CSF and serum samples were collected from each
stroke patient within 30 min of admission, and the
diagnosis was confirmed by brain CT performed within
the next 30 min. Thus the laboratory and neuroimag-
ing data were obtained in a uniform manner in all
the stroke patients within the first 24 hours of stroke.
All the patients had complete ischaemic stroke
defined as clinical symptoms persisting for > 24 hours
[5]. The exclusion criteria consisted of CNS, inflam-
matory, immunological and malignant diseases, in-
fections, severe renal or hepatic failure, tissue inju-
ry-related conditions within the previous year and
immunosuppression, as well as treatment with anti-
inflammatory drugs within the previous 6 months.
A total of 15 tension headache subjects (mean
age ± SD: 70.1 ± 8.6 years, 11 women) were includ-
ed as a control group. The same exclusion criteria were
applied to the controls as to the stroke patients. In all
control subjects CT of the brain was also performed
and this revealed no pathological changes.
The study was performed on the basis of the in-
formed consent of all the stroke patients or their
relatives and of all the control subjects and the ap-
proval of the Ethics Committee of the University
School of Medicine in Poznań.
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Laboratory procedure
CSF samples from the stroke patients and con-
trols were centrifuged immediately after lumbar
puncture and stored at –80oC. Venous blood sam-
ples from the stroke patients and controls were al-
lowed to clot at room temperature for 30 min, and,
after being centrifuged for 10 min, the obtained se-
rum was stored at –80oC.
CXCL5 levels in CSF and serum samples were
quantified by ELISA (Quantikine R&D Systems, Min-
neapolis, MN, USA) according to the manufactur-
er’s instructions and examined in duplicate. The sen-
sitivity of the method was 15.0 pg/ml.
Evaluation of the volume of
early brain CT hypodense areas
Brain CT scans were carried out parallel to the
orbitomeatal line using a 10 mm (supratentorial) and
5 mm (infratentorial) slice thickness. Each ischaemic
stroke patient, with the exception of one with ra-
diologically invisible changes, presented an anatom-
ically relevant single early CT hypodense area loca-
lised in the cerebral hemisphere within the blood
supply territory of the middle or anterior cerebral
artery and displayed no other CT changes.
The volume (given in ccm) of early brain CT hy-
podense areas was calculated according to the for-
mula based on length × depth × height (in mm) of
the area measurements [19]. The measurements of
the hypodense areas and calculations of their vol-
ume were performed twice with the difference not
exceeding 5%.
Statistical analysis
As the obtained data on CSF and serum CXCL5 lev-
els in the stroke patients were not normally distribut-
ed, analysis was performed with non-parametric tests.
The Mann-Whitney U test was used to compare
CXCL5 levels in CSF and serum in the stroke patients
with control values. The Spearman rank-order corre-
lation test was applied to calculate the correlation
between CSF CXCL5 levels in the stroke patients and
the volumes of early brain CT hypodense areas. The
results are presented as mean ± SD and p < 0.05
was considered statistically significant.
RESULTS
CSF and serum CXCL5 levels in patients within
the first 24 hours of ischaemic stroke and in
the control group
CSF CXCL5 levels in the stroke patients were sig-
nificantly (p > 0.001) higher in comparison with
those of the control group, whereas serum CXCL5
levels in the stroke patients did not differ significantly
from those in the controls (Table 1).
The volume of early brain CT hypodense areas
in patients within the first 24 hours of
ischaemic stroke
Brain CT analysis revealed the average early brain
CT hypodense area volume to be 10.0 ± 10.7 ccm.
The largest volume of a hypodense area was
37.5 ccm, whereas the smallest was 0.6 ccm.
Correlation between CSF CXCL5 levels and
the volume of early brain CT hypodense areas
in patients within the first 24 hours of
ischaemic stroke
CSF CXCL5 levels in patients within the first
24 hours of ischaemic stroke correlated positively
with the volume of early brain CT hypodense areas
observed at the same period (r = 0.96; p < 0.0001).
The correlation is shown in Figure 1.
DISCUSSION
An increase in CXCL5 levels in CSF of patients with-
in the first 24 hours of ischaemic stroke suggests
Table 1. CSF and serum CXCL5 levels [pg/ml] in patients
within the first 24 hours of ischaemic stroke and in the
control group; *p < 0.001
Stroke patients Control group
CSF 38.2 ± 18.4* 18.7 ± 8.2
Serum 1238.8 ± 309.3 1049.3 ± 430.3
Figure 1. Correlation (r) between CSF CXCL5 levels [pg/ml] and
the volume of early brain CT hypodense areas [ccm] in patients
within the first 24 hours of ischaemic stroke.
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chemokine upregulation during the early phase of
the disease and is in line with the reported eleva-
tions in CSF levels of other CXC chemokines express-
ing the ELR motif, such as CXCL1 [growth-related
oncogene-alpha (GRO-alpha)] [13] and CXCL8 [in-
terleukin-8 (IL-8)] [11, 20] in patients with acute ce-
rebral ischaemia.
An increase in CXCL5 levels in the studied body
fluids of stroke patients was restricted to CSF and
did not occur in the serum. Such result indicates the
presence of CXCL5 over-production by cells within
the central nervous system (CNS) and the absence
of CXCL5 over-production by peripheral blood cells
during the early phase of ischaemic stroke.
An intracerebral synthesis of CXCL5 following
acute cerebral ischaemia could be a result of the in-
flammatory response to stroke. The response is me-
diated by stroke-activated CNS-resident cells and is-
chaemic brain-infiltrated leukocytes producing nu-
merous inflammatory molecules including chemo-
kines [10, 16, 22].
The cellular origins of CXCL5 within ischaemic
brain are unknown. However, Albright and Gonza-
lez-Scarano [2] have recently shown that activated
microglial cells and monocyte-derived macrophag-
es are able to upregulate CXCL5 gene expression.
Furthermore, Lu et al. [14] have reported that the
transcription and translation of genes for several CXC
chemokines expressing ELR motif take place in as-
trocytes.
CXCL5, with its intrathecal origination in stroke
and potent neutrophil chemoattractant properties,
appears to be, like other intracerebrally synthesised
chemokines, both the product and the mediator of
the neuroinflammation involving leukocyte accumu-
lation within ischaemic brain. Hence, in view of the
previous data documenting neutrophils as beginning
their migration into the ischaemic tissue within hours
of cerebral infarct and peaking at the 24th hour after
disease onset [1, 10], the finding that there is an
increase in CSF CXCL5 levels in patients within the
first 24 hours of stroke could be expected to occur
and suggests an involvement of this chemokine in
attracting neutrophils to the sites of cerebral is-
chaemia.
In response to stroke, numerous chemokines and
pro-inflammatory cytokines are expressed, and
there is mutual interference, contributing to the de-
velopment of post-stroke inflammation [9, 10, 16].
CXCL5 may act together with other chemokines, in-
cluding CXCL1 and CXCL8; both of these chemokines
are thought to be involved in the ischaemic brain
infiltration with neutrophils [11, 13, 20]. Moreover,
studies in vitro have demonstrated the reciprocal
cross-talk between the chemokine CXCL5 and tu-
mour necrosis factor-alpha (TNF-alpha), the cytok-
ine-initiating neuroinflammation in stroke [7, 17].
Early brain CT hypodense areas identified within
hours of stroke represent evolving ischaemic brain
damage together with perilesional oedema [21]. Both
these consequences of stroke are augmented by post-
stroke pathophysiological mechanisms, including
inflammation with tissue infiltration by leukocytes,
particularly neutrophils producing a number of bio-
active substances such as toxic oxygen metabolites,
destructive enzymes, and pro-inflammatory cytok-
ines with neurotoxic properties [4].
A positive correlation between CSF CXCL5 levels
and the volume of early brain CT hypodense areas in
patients within the first 24 hours of stroke suggests
chemokine participation in the mechanisms contrib-
uting to the extent of ischaemic brain damage.
This is the first report devoted to CXCL5 in stroke,
and further studies are required to confirm the det-
rimental role of this chemokine in acute cerebral is-
chaemia.
Nevertheless, the data presented a rapid in-
crease in CXCL5 levels in the CSF of ischaemic stroke
patients and the relationship between the chemok-
ine level and the size of early brain damage sug-
gests that CXCL5 may be involved in the inflam-
matory reaction accompanying acute ischaemic
stroke.
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